

Drug-eluting Balloons Versus Drug-eluting Stents in Patients with Restenosis after Implantation of a Drug-eluting Stent

Abid Assali, Hana Vaknin-Assa, Tamir Bental, Igal Teplitsky, David Brosh, Eli Lev,
Ran Kornowski
*Cardiology, Rabin Medical Center, Petah-Tikva, and The Sackler Faculty of Medicine,
Tel-Aviv University, Israel*

Background:

The best way to treat restenosis [ISR] in patients who have previously received a drug-eluting stent [DES] is unknown. We compared the efficacy of drug-eluting balloons (DEB) versus DES in these patients.

Methods:

A series of 157 consecutive patients with ISR lesions in previously implanted DES were analyzed. 31 patients were treated by DEB and 126 by DES. Treatment was decided by operator discretion. Major adverse cardiac events (MACE) were defined as death, myocardial infarction, and the need for target lesion revascularization were analyzed at 6 months.

Results:

	DEB [n=31]	DES [n=126]	P-value
Age	67±11	65±10	0.3
Male	81%	78%	0.7
DM	45%	49%	0.7
ACS	61%	65%	0.9
6 month cardiac death	3.2%	0.8%	0.2
6 month MI	3.7%	3.2%	0.9
6 month Stent thrombosis	0%	1.6%	0.5
6 month TVR	6.4%	9.5%	0.7
6 month CABG	0%	1.6%	0.5
6 month MACE	9.7%	11.1%	0.9

Conclusions:

DEB could be an effective treatment for patients with ISR after DES implantation.